Literature DB >> 18555812

Effects of two low-dose combined oral contraceptives containing drospirenone on bone turnover and bone mineral density in young fertile women: a prospective controlled randomized study.

Virginia Gargano1, Mariangela Massaro, Ilaria Morra, Carmen Formisano, Costantino Di Carlo, Carmine Nappi.   

Abstract

BACKGROUND: The effects of a 21-day combined oral contraceptive containing 30 mcg ethinyl estradiol plus 3 mg drospirenone with a 21-day preparation containing 20 mcg ethinyl estradiol plus 3 mg drospirenone on bone turnover and bone mineral density (BMD) in young fertile women were compared.
METHODS: A randomized, controlled trial was conducted on healthy fertile women treated with 30 mcg ethinyl estradiol plus 3 mg drospirenone (Group A; n=21), 20 mcg ethinyl estradiol plus 3 mg drospirenone (Group B; n=23) and healthy controls (Group C; n=21). At 3, 6, 9 and 12 months, serum and urinary calcium, osteocalcin (BGP), urinary pyridinoline and deoxypyridinoline were measured. At baseline and after 12 months, lumbar bone mineral density was determined by dual-energy X-ray absorptiometry.
RESULTS: In Groups A and B, urinary pyridinoline and deoxypyridinoline at 6, 9 and 12 months were significantly reduced in comparison with basal values and Group C (p<.05). In Groups A and B, serum calcium levels were significantly increased after 6 months. No significant difference was detected between Groups A and B in urinary levels of pyridinoline and deoxypyridinoline, in calcium levels and in BGP levels. At 12 months, no significant difference was detected in spinal BMD values between the three groups and in comparison with basal values.
CONCLUSION: Both combined oral contraceptives exert a similar positive influence on bone turnover in young postadolescent women.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18555812     DOI: 10.1016/j.contraception.2008.01.016

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  7 in total

Review 1.  Update on hormonal contraception and bone density.

Authors:  Michelle M Isley; Andrew M Kaunitz
Journal:  Rev Endocr Metab Disord       Date:  2011-06       Impact factor: 6.514

2.  Oral contraceptive use, bone mineral density, and bone turnover markers over 12 months in college-aged females.

Authors:  Hawley C Almstedt; Makenzie M Cook; Lily F Bramble; Deepa V Dabir; Joseph W LaBrie
Journal:  J Bone Miner Metab       Date:  2020-01-25       Impact factor: 2.626

3.  Long-term tolerability of ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen: results from a randomised, controlled, multicentre study.

Authors:  Christine Klipping; Ingrid Duijkers; Michel P Fortier; Joachim Marr; Dietmar Trummer; Jörg Elliesen
Journal:  J Fam Plann Reprod Health Care       Date:  2012-04

4.  Are the Effects of Oral and Vaginal Contraceptives on Bone Formation in Young Women Mediated via the Growth Hormone-IGF-I Axis?

Authors:  Heather C M Allaway; Madhusmita Misra; Emily A Southmayd; Michael S Stone; Connie M Weaver; Dylan L Petkus; Mary Jane De Souza
Journal:  Front Endocrinol (Lausanne)       Date:  2020-06-16       Impact factor: 5.555

5.  Consensus Statement on the Use of Oral Contraceptive Pills in Polycystic Ovarian Syndrome Women in India.

Authors:  Duru Shah; Madhuri Patil
Journal:  J Hum Reprod Sci       Date:  2018 Apr-Jun

6.  Combined hormonal contraceptives use and bone mineral density changes in adolescent and young women in a prospective population-based Canada-wide observational study.

Authors:  Tatjana S Brajic; Claudie Berger; Katharina Schlammerl; Heather Macdonald; Shirin Kalyan; David A Hanley; Jonathan D Adachi; Christopher S Kovacs; Jerilynn C Prior
Journal:  J Musculoskelet Neuronal Interact       Date:  2018-06-01       Impact factor: 2.041

7.  Unique effects on hepatic function, lipid metabolism, bone and growth endocrine parameters of estetrol in combined oral contraceptives.

Authors:  Marie Mawet; Catherine Maillard; Christine Klipping; Yvette Zimmerman; Jean-Michel Foidart; Herjan J T Coelingh Bennink
Journal:  Eur J Contracept Reprod Health Care       Date:  2015-07-27       Impact factor: 1.848

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.